GlassScriptPhysician profile
Rup Kumar Nagala
NPI 1336138601
$548.98
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $87.14 · 2021: $59.54 · 2023: $18.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.32 | 2019-2020 | |
| Pfizer INC. | $95.47 | 2019-2020 | |
| Novo Nordisk INC | $71.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $59.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.96 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.33 | 2019 | |
| Celgene Corporation | $18.88 | 2023 | Reblozyl |
| Nevro Corp. | $14.46 | 2019 | |
| Tactile Systems Technology INC | $12.58 | 2019 | |
| Mylan Specialty L.P. | $12.50 | 2019 | |
| Lilly USA, LLC | $12.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.20 | 2019 | |
| Alkermes, INC. | $11.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rup Nagala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.